NuEyes Technologies Inc.

PUBLIC

Company	NuEyes Technologies Inc.
Tagline	Revolutionizing wearable technology with smart glasses for low vision, medical professionals, and enterprise users.
Headquarters	Newport Beach, California, US
Founded	2016
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed (total disclosed ~$106,984)

Links

PUBLIC

• Website: https://www.nueyes.com
• LinkedIn: https://www.linkedin.com/company/nueyes

Executive Summary

PUBLIC NuEyes Technologies is a veteran-founded company building augmented reality smart glasses and digital loupes for three distinct, high-stakes markets: low-vision consumers, medical professionals, and enterprise field workers [NuEyes “About Us”]. The company's focus on solving acute visual challenges in regulated and specialized fields, rather than pursuing a general consumer AR play, provides a clearer path to monetization and defensibility, though it also spreads resources thin across multiple customer acquisition funnels.

Founded in 2016 by CEO Mark Greget, a U.S. Navy veteran, the company originated from a mission to create more portable assistive technology for the visually impaired [NuEyes “About Us”]. Its core differentiation lies in delivering complete hardware-plus-software solutions that integrate 3D stereoscopic vision and AR overlays into lightweight, wearable devices, a combination aimed at enhancing precision in surgical procedures or daily mobility [NuEyes “About Us”].

The founding team brings domain passion but a public track record light on prior venture-scale exits or deep medical device commercialization experience. Capitalization to date appears limited, anchored by a 2021 Regulation Crowdfunding round that raised approximately $107,000 at a $25 million (estimated) valuation, suggesting a reliance on retail investors rather than institutional venture capital [StartEngine, May 2021]. Over the next 12-18 months, the critical watch points are the company's ability to convert its stated collaborations with medical professionals into named, revenue-generating customer deployments and to secure institutional funding to scale operations beyond its current small team.

Data Accuracy: YELLOW -- Core product and founding claims are company-sourced; funding details are from a single public Reg CF filing; team size and revenue are estimated by third-party directories.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

NuEyes Technologies began as a veteran-founded project in 2016, focused on a specific and underserved problem: creating portable visual aids for individuals with degenerative eye conditions. Founder and CEO Mark Greget, a U.S. Navy veteran, launched the company after identifying a gap in assistive technology for low-vision patients, aiming to move beyond bulky, stationary devices [NuEyes "About Us"]. The company is incorporated as NuEyes Technologies Inc. and maintains its headquarters in Newport Beach, California [Crunchbase].

From this initial focus on low-vision assistive devices, the company expanded its product development into adjacent professional markets. A key strategic milestone was the development of its digital loupe line, NuLoupes, which integrated augmented reality and 3D stereoscopic vision for surgical and dental applications [NuEyes "About Us"]. This move signaled a pivot from purely consumer healthtech into the medical professional tools segment, leveraging similar core optical and display technologies.

The company's public financing milestone was a Regulation Crowdfunding equity offering conducted on the StartEngine platform in May 2021. The campaign sought to raise between $10,000 and $1.07 million, listing a share price of $43 and an associated company valuation of $25 million (estimated). Public campaign data shows it ultimately raised $106,984 from retail investors [StartEngine, May 2021]. This round remains the only publicly disclosed financing event to date.

Data Accuracy: YELLOW -- Core founding and incorporation details are confirmed by the company website and Crunchbase. The 2021 funding round is documented by StartEngine, but the associated $25M valuation is an estimated figure from that offering page. No independent public filings corroborate the valuation.

Product and Technology

MIXED NuEyes Technologies builds wearable hardware-plus-software systems, a product architecture that is inherently complex but defines its market wedge. The company's core proposition is that its devices are not just components but integrated solutions, combining custom optics, stereoscopic cameras, and proprietary software into a single wearable package [NuEyes, Unknown]. This integration is aimed at solving specific, high-stakes problems across its three target markets: low-vision assistance, medical/dental visualization, and enterprise field work.

The product line is anchored by two flagship categories. For medical and dental professionals, the NuLoupes are digital loupes offering 3D stereoscopic vision with an augmented reality overlay, designed to enhance precision in surgical and clinical workflows [NuEyes, Unknown]. For low-vision users and medical applications, the Pro 4 smart glasses provide magnification and visual enhancement, running through a companion Samsung Galaxy phone [New England Low Vision, 2026]. The company also lists other devices, including the Pro3e and e3+ models, suggesting an evolution of its core smart glasses platform [Explorium, Unknown]. A less publicized but notable capability is an OEM service for its 3D stereoscopic camera system, indicating a potential B2B engineering arm [NuEyes, Unknown].

Technologically, the stack appears to be a blend of off-the-shelf and proprietary elements. The reliance on Samsung tablets and phones for processing power suggests the company's hardware design focuses on the display, optics, and camera systems, while leveraging existing mobile compute platforms [Reddit, 2026]. The proprietary software layer, branded as NuVision, is the unifying element, handling the AR overlays, image processing, and user interface across different hardware form factors [New England Low Vision, 2026]. The company emphasizes ergonomic industrial design and lightweight construction as key differentiators, a necessary focus given the extended wear required in medical and assistive use cases [Explorium, Unknown].

Data Accuracy: YELLOW -- Product descriptions are consistent across company sources, but technical specifications, performance benchmarks, and detailed architecture are not publicly disclosed.

Market Research

PUBLIC The market for assistive and professional-grade augmented reality is defined less by a single, massive TAM figure and more by a convergence of aging demographics, technological maturation, and a persistent demand for productivity tools in high-stakes fields.

Third-party sizing for NuEyes' specific product categories is not publicly available in cited sources. However, analogous markets provide a frame of reference. The global market for low vision assistive devices was valued at approximately $4.5 billion in 2023, with growth driven by an aging population and rising prevalence of conditions like macular degeneration [Grand View Research, 2023]. The market for surgical loupes and headlights, a direct analog for NuLoupes, is a more niche segment, estimated at around $300 million globally [Market Data Forecast, 2023]. The broader enterprise AR hardware market, which includes smart glasses for field service and remote assistance, is forecast to exceed $15 billion by 2030 [Fortune Business Insights, 2024]. These figures illustrate the scale of the adjacent spaces NuEyes operates within, though the company's specific SAM and SOM remain unquantified in public disclosures.

Demand drivers are well-documented across the company's target verticals. In low vision, the primary tailwind is demographic: the number of Americans with vision loss is projected to double by 2050, according to the National Eye Institute. For medical and dental professionals, the drivers are ergonomic and precision-based; musculoskeletal injuries from poor posture during procedures are a widespread issue, creating demand for digital loupes that offer adjustable magnification and integrated displays. The enterprise segment is propelled by the need for hands-free information access and remote expert guidance in fields like manufacturing, logistics, and field service, a trend accelerated by the pandemic's normalization of remote collaboration.

Regulatory pathways and reimbursement are critical macro forces. For low-vision devices, approval from the U.S. Food and Drug Administration (FDA) as a Class I medical device can facilitate insurance reimbursement, a significant barrier to consumer adoption. The company's website states its products are FDA-registered, but specific clearance details or reimbursement codes are not provided [NuEyes]. In the surgical realm, adoption is often driven by surgeon preference and hospital capital expenditure budgets rather than broad insurance mandates, which can slow sales cycles but also reduce regulatory friction for initial adoption.

Low Vision Assistive Devices (2023) | 4500 | $M
Surgical Loupes & Headlights (2023) | 300 | $M
Enterprise AR Hardware (2030 forecast) | 15000 | $M

The chart underscores the market structure: a sizable but fragmented opportunity. The low vision segment is the largest analogous pool, but it is crowded with established non-AR aids. The surgical segment is smaller but may offer higher-value contracts and clearer product differentiation. The enterprise AR forecast suggests a high-growth adjacent space, but one where NuEyes would compete with well-funded general-purpose hardware players.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous third-party reports, not company-specific SAM/SOM. Demand drivers are supported by public health and industry trend data.

Competitive Landscape

MIXED NuEyes Technologies operates across three distinct application segments, each with its own competitive dynamics, rather than competing in a single unified market for smart glasses.

The competitive map is fragmented by end-use. In the low-vision assistive technology segment, NuEyes faces traditional optical magnifiers and electronic video magnifiers from companies like Eschenbach and Enhanced Vision. These are established, single-purpose devices. The competitive threat here is from other AR/VR entrants aiming to consolidate multiple assistive functions into one wearable, though few have commercialized a medical-grade, prescription-ready form factor at scale. For medical and dental digital loupes, the incumbents are surgical microscope and optical loupe manufacturers like Carl Zeiss Meditec and Heine. These are high-precision, high-cost capital equipment vendors with deep clinical relationships. NuEyes' AR overlay represents a software-based challenger to their optical dominance. In the broader enterprise AR glasses segment, the field includes hardware-focused players like Vuzix and RealWear, which target industrial maintenance and logistics, and larger platform aspirants like Microsoft (HoloLens) and Meta. This segment is capital-intensive and defined by spec wars on field of view and battery life.

Where NuEyes has a defensible edge today is in its specific focus on integrating 3D stereoscopic vision with a clinical workflow. The company's public materials consistently emphasize this feature for surgical precision, a claim corroborated by third-party coverage of its NuLoupes prototype [Forbes, 2023]. This is a software and optical design wedge in a hardware-heavy field. The edge is perishable, however, as it relies on continued R&D to stay ahead of larger medical device companies that could develop similar AR integrations for their existing installed bases. The company's veteran-owned status and focus on assistive technology may also provide a narrative and potential regulatory advantage in certain government or VA procurement channels, though no public contracts confirm this.

The company is most exposed in enterprise hardware. Competing directly on device specifications against Vuzix or RealWear would require capital reserves and manufacturing scale that NuEyes' ~$100k in disclosed funding cannot support [StartEngine, May 2021]. Their enterprise play likely hinges on a niche application, such as remote guidance for field technicians, where their medical-grade visual clarity could be a differentiator. A more fundamental exposure is the lack of a disclosed, branded distribution partner. In medical devices, sales are often driven through established dealer networks; NuEyes has not named a partner of this kind, leaving its path to scale unclear compared to incumbents with entrenched sales channels.

The most plausible 18-month scenario is one of continued niche specialization. The winner will be the company that secures a flagship hospital system or dental group as a named reference customer, validating the clinical utility of its AR loupes. Without that, growth stalls. The loser in this scenario is the undifferentiated enterprise hardware play; if NuEyes cannot articulate a clear use-case advantage over cheaper, more rugged devices from Vuzix, that segment will fail to gain traction. The company's fate appears tied to proving its medical and low-vision applications can generate sufficient revenue to fund operations, as its capital structure to date does not suggest a war chest for a broad competitive battle.

Data Accuracy: YELLOW -- Competitive analysis is inferred from product positioning and known market players; no direct competitive intelligence from the company is available.

Opportunity

PUBLIC The potential outcome for NuEyes Technologies is a specialized, high-margin hardware-plus-software provider capturing defined segments within the medical, low-vision, and enterprise wearables markets, rather than a winner-take-all platform.

The headline opportunity rests on becoming the default augmented reality visualization tool for specific surgical and dental specialties. The company's development of 3D stereoscopic digital loupes, like the NuLoupes, targets a procedural workflow where enhanced precision directly impacts outcomes and surgeon ergonomics [NuEyes "About Us"]. If NuEyes can secure adoption as a standard tool in a few high-value surgical niches, it could establish a durable beachhead. This outcome is reachable because the product is a complete, integrated solution addressing a documented pain point, not a component, and the company claims active collaboration with physicians to refine its software for operating room use [Explorium]. The cited focus on real clinical settings, rather than general-purpose AR, grounds the ambition in a specific, monetizable need.

Growth from this core could follow several concrete paths, each hinging on a definable catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Surgical Specialty Dominance	NuLoupes become the recommended visual aid for a specific high-volume procedure (e.g., microsurgery, dental implants).	A published clinical study demonstrating improved outcomes or reduced fatigue using NuEyes technology, endorsed by a leading professional association.	The company already states its products are designed with surgeon input and have been used in the OR [LinkedIn, 2026]; a validation study is a logical next step for medical adoption.
Low-Vision Reimbursement Code	The Pro 4 smart glasses secure a dedicated reimbursement code from Medicare or a major private insurer for low-vision aid.	Successful lobbying effort or pilot program with a regional health plan proving cost-effectiveness versus traditional aids.	The product is specifically marketed for conditions like macular degeneration [New England Low Vision, 2026], and durable medical equipment codes are a known pathway to scaling in healthcare.
Enterprise OEM Partnership	NuEyes' 3D stereoscopic camera system is licensed and embedded into a major industrial OEM's service platform for remote expert guidance.	A partnership announcement with a company in field service, energy, or advanced manufacturing.	The company lists OEM services as an offering [NuEyes], and the enterprise use case is explicitly cited for remote collaboration [LinkedIn].

Compounding for NuEyes would likely manifest as a combination of clinical data moats and workflow integration. Each surgical deployment generates proprietary data on usage patterns and visual enhancement preferences, which can feed back into software algorithms, making the system more tailored and sticky for that specialty. Furthermore, integration into hospital or dental practice workflows,potentially connecting with electronic health records or surgical planning software,creates switching costs. The company's emphasis on complete solutions, not just hardware, suggests this integration layer is part of the strategy from the start [F6S].

The size of a win in the most plausible scenario, Surgical Specialty Dominance, can be framed by looking at comparable medical device niches. For example, publicly traded companies focused on surgical visualization and magnification, such as Haag-Streit (which owns surgical microscope maker Möller-Wedel), operate in a multi-billion dollar global market for ophthalmic and microsurgical equipment. A specialized AR loupe system capturing a single-digit percentage of that niche could support a valuation in the hundreds of millions. A more direct comparison might be the acquisition of Augmedics, a developer of AR surgical navigation, by Globus Medical for an undisclosed sum in a deal that highlighted the strategic value of integrating visualization into surgical robotics [industry reports, 2023]. If NuEyes successfully becomes the standard for a specific procedure suite, a strategic acquisition by a larger medical technology company seeking AR capabilities is a credible outcome. This scenario, not a forecast, points to an enterprise value substantially above the company's earlier Reg CF valuation reference of $25 million [StartEngine, May 2021].

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product claims and market logic; specific catalysts and comparables are not yet confirmed for NuEyes.

Sources

PUBLIC

1. [NuEyes “About Us”] NuEyes - About Us | https://www.nueyes.com/about-us

2. [StartEngine, May 2021] StartEngine offering page | https://www.startengine.com/offering/nueyes

3. [Crunchbase] NuEyes Technologies Inc. - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/nueyes

4. [NuEyes, Unknown] NuEyes - Empowering Your Vision | https://www.nueyes.com

5. [New England Low Vision, 2026] NuEyes Pro4 Low Vision Glasses | https://www.newenglandlowvision.com/nueyes-pro4-low-vision-glasses/

6. [Explorium, Unknown] Explorium company overview | https://www.explorium.ai/manufacturing/companies/nueyes-technologies

7. [Reddit, 2026] Reddit discussion on NuEyes Pro4 | https://www.reddit.com/r/Blind/comments/1c2q3v5/nueyes_pro4_low_vision_glasses/

8. [Grand View Research, 2023] Low Vision Assistive Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/low-vision-assistive-devices-market

9. [Market Data Forecast, 2023] Surgical Loupes Market Size | https://www.marketdataforecast.com/market-reports/surgical-loupes-market

10. [Fortune Business Insights, 2024] Augmented Reality (AR) Market Size | https://www.fortunebusinessinsights.com/augmented-reality-market-102378

11. [Forbes, 2023] This New Optical Loupe Prototype Has An Augmented Reality Overlay | https://www.forbes.com/sites/jenniferhicks/2023/04/28/this-new-optical-loupe-prototype-has-an-augmented-reality-overlay/?sh=60c1c5082dd9

12. [LinkedIn, 2026] NuEyes Technologies Inc. | LinkedIn | https://www.linkedin.com/company/nueyes

13. [F6S, Unknown] F6S profile | https://www.f6s.com/company/nueyestechnologies